Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Biotechnology

Healthcare
$0.46 -0.01%

-$0.00 today

Market cap
$57.32M
Beta
0.96
P/E (TTM)
-2.5
EPS (TTM)
-$0.52
52W Low $1.00High $3.06

Volume 2.23M

Average 1.99M

MIST Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Milestone Pharmaceuticals Inc.NASDAQ: MIST

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures growth accelerates

Q1 FY2026 capital expenditures of $45K (cash outflow) rose 650.0% year over year, ahead of the +76.9% change in trailing-twelve-month capital expenditures. Sequentially, it rose 309.1% from the prior quarter. Over 3 fiscal years it compounded at +3.5% a year.

Context

  • Capital expenditures amounted to 19.5% of revenue in FY2025.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +650.0% holds above the trailing-twelve-month pace of +76.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$45K+309.1% QoQ
Last fiscal yearDec 2025
-$302K+815.2% YoY
LTMMar 2026
-$68.98K+76.9% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+650.0%——
1 year+815.2%——
3-year CAGR+3.5%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(302K) USD
Year-over-year change
-815.2%

Capital Expenditures vs competitors

How MIST compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +76.9% is the highest of 6, against a peer median of -75.6%.
  • Capital expenditures amounts to 3.9% of revenue for MIST, versus a peer median of 4.8%.
MIST Competitors
Capital Expenditures for MIST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MOLNMolecular Partners AGLTM Mar 2026CHF 333.55K CHF-67.9%-20.4%—
PEPGPepGen Inc.LTM Mar 2026$139K USD-75.6%-58.7%—
IPHAInnate Pharma S.A.FY2025€134.47K EUR-65.6%-50.7%4.8%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$68.98K USD+76.9%+3.5%3.9%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$52K USD-82.7%-62.1%1.6%
CRDFCardiff Oncology, Inc.LTM Mar 2026$44K USD—-63.3%8.4%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$16K USD-81.6%-71.0%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$13K USD—-19.6%—
Peer median (excluding MIST) —-75.6%-58.7%4.8%

Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(42.85M)(58.39M)(59.69M)(41.52M)(63.06M)
Depreciation & Amortization362K89K92K105K114K
Deferred Income Tax00000
Stock-Based Compensation7.28M9.05M9.53M5.78M7.46M
Change in Working Capital1.62M(3.26M)1.24M3.66M2.68M
Accounts Receivables96K(730K)(2.64M)1.46M(1.12M)
Inventory0000(648K)
Accounts Payables00004.43M
Other Working Capital1.52M(2.53M)3.88M2.2M17K
Other Non-Cash Items368K44K2.39M3.13M3.76M
Operating Cash Flow(33.22M)(52.47M)(46.42M)(28.85M)(49.04M)
Capital Expenditures0(272K)(112K)(33K)(302K)
Acquisitions (Net)00000
Purchases of Investments(15M)(85.85M)(137.13M)(113.55M)(82.92M)
Sales of Investments85M29M142M121.87M94.47M
Other Investing Activities00000
Investing Cash Flow70M(57.12M)4.76M8.28M11.25M
Debt Repayment0050M00
Common Stock Issued02.63M027.26M85.53M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.06M458K(2.21M)4.86M0
Financing Cash Flow5.06M3.09M47.79M32.12M85.53M
Effect of Forex Changes00000
Net Change in Cash41.83M(106.51M)6.12M11.55M47.73M
Free Cash Flow(33.22M)(52.74M)(46.54M)(28.88M)(49.34M)

Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Intrinsic Alpha fair value

Locked

Current Price

$0.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.